Back

Biventricular hemodynamic phenotyping of transthyretin amyloid cardiomyopathy vs. HFpEF: a pilot invasive pressure-volume loop analysis

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Haemodynamic determinants in heart failure Haemodynamics of Heart Failure Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Fredrik Edbom

Umea University, Umea (Sweden)

6 More presentations in this session

Presentation thumbnail
Long-term hemodynamic trends after LVAD implantation
Mr S. Legtenberg (Groningen, NL)
Abstract
Presentation thumbnail
Assessment of stroke volume and cardiac output in real-world HF patients: a comparison of bioimpedance methods, 2D/3D echocardiography, and thermodilution in patients with sinus rhythm and AF
Doctor M. Vitolo (Modena, IT)
Abstract
Presentation thumbnail
The independent role of right ventricular to pulmonary artery coupling for heart failure with improved ejection fraction
Doctor C. Harsan (Bucharest, RO)
Abstract
Presentation thumbnail
Long-term prognostic implications of right atrial pressure measured during emergency hemodynamic assessment
Assistant Professor H. Sato (Matsue, JP)
Abstract
Presentation thumbnail
Invasively assessed pulmonary hypertension as an independent prognostic determinant in ambulatory patients with advanced heart failure
Doctor P. Manca (Palermo, IT)
Abstract

Access the full session

Session thumbnail
Haemodynamic determinants in heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Session
Bridging gaps in heart failure care: primary care trends, exercise, kidney function, and global health perspectives
thumbnail
Congress Session
Which device might help your HFpEF patient?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources